



Semintra[®]—designed with cats and owners in mind


The first and only liquid solution for the management of chronic kidney disease* in cats



*Reduction of proteinuria associated with chronic kidney disease in cats.



Contents



CHRONIC KIDNEY DISEASE

HEALTH CHECK PROGRAMME

MANAGING CKD WITH SEMINTRA

MODE OF ACTION


QUALITY OF LIFE AND COMPLIANCE

SEMINTRA: BENEFITS SUMMARY


CKD is very common in cats



- Early recognition is vital:
 - Prompt treatment may slow disease progression¹
 - Survival is related to the severity of proteinuria²
- Treatment will help maintain the quality of life of cat and owner



The 4 stages of feline CKD progression



At the later stages of the disease, clinical signs increase and life expectancy decreases⁴⁻⁶

*Median life expectancy at diagnosis based on IRIS stage following rehydration with fluid therapy.

Introduce a health check programme for CKD



International guidelines recommend regular clinic assessment and screening of ageing cats over 7 years of age for chronic diseases^{3,7,8}

EMPOWER CLINIC
SUPPORT STAFF

1

SCREENING
AND REGULAR
ASSESSMENT

2

TREAT AND
FOLLOW UP

3

1 Empower clinic support staff



Gather contact details of all owners with **cats over 7 years of age**



Invite cats and owners for screening visits/health visits and explain:

- Outward signs of CKD are not seen until very late
- CKD impacts the quality of life and lifespan of affected cats and is more prevalent as cats age
- Early disease detection is only possible via clinic assessment



Engage with cat owners proactively to maximise overall patient care and clinic potential

② Screening and regular assessment



Guidelines recommend the following procedures for cats over 7 years^{3,7}:



Physical examination

- Record body weight and hydration




Urine analysis

- USG
- UP:C



Blood sample

- PCV, total protein, SDMA, urea and creatinine



Perform further tests

- Blood pressure
- Renal Echo if available



Advise 6–12-monthly screening for patients with no evidence of CKD

③ Treat and follow up



Maximise patient outcomes via regular vet visits



Start patients with evidence of chronic RAAS activation / CKD*
on **Semintra**




Reassure daily treatment compliance provides the best health
benefits for their cat and maintains quality of life



Semintra is central in the management of CKD

Semintra is central to the management of feline CKD¹



SEMINTRA, A RENAL DIET/SUPPLEMENT AND INCREASED FLUID INTAKE PROVIDE **HOLISTIC MANAGEMENT FOR CKD**



*From studies in humans and rodents.

Managing CKD with Semintra



Use Semintra when prescribing a renal diet or if there is any of the following:



Clinical signs of **CKD**, such as polyuria (PU), polydipsia (PD) and weight loss^{3,5}




Elevated **SDMA** with high, normal or elevated creatinine and a urine specific gravity (**USG**) <1.035 ^{3,6}




Urine protein to creatinine ratio (**UP:C**) ≥ 0.2 ^{3,6}

Semintra's targeted MOA harnesses the protective benefits of the RAAS




Semintra breaks with vicious cycle of CKD




*Reduced tissue inflammation.

Semintra improves quality of life



Cat owners reported maintenance or improvement of¹⁰:



ADMINISTER SEMINTRA EARLY TO MAXIMISE KIDNEY HEALTH TO PROMOTE AN IMPROVED QUALITY OF LIFE

*Appetite was perceived to be maintained in 51% of cats and improved in 40% of cats, and activity levels were perceived to be maintained in 51% of cats and improved in 41% of cats.

Semintra is an ideal solution for cats and cat owners



- Well accepted liquid formulation
- Easy to draw up and administer directly into the mouth or over a small amount of food
- Drives cat owner compliance and improves quality of life¹⁰

THE STATISTICS:




PREFERRED
LIQUID
MEDICATION
TO TABLETS¹⁰



EASILY
MEDICATED
THEIR CAT¹⁰



Semintra—the unique solution for feline CKD*



Disease

- **CKD is a very common, progressive and silent disease**
- **The disease is triggered by chronic RAAS activation** and detracts from the quality of life of both cat and owner
- Guidelines recommend **screening programmes to promote early detection and management**

Proven and protective


- Semintra has **strong clinical evidence** of safety and efficacy
- Semintra's targeted mode of action **works with the RAAS, harnessing its protective benefits**, not blocking or bypassing it
- Semintra is **safe for long-term use** as it is almost exclusively excreted via the faeces to protect renal function

Easy and well accepted


- Semintra promotes better compliance and quality of life as it:**
- **Is easy to give and well accepted** by >90% of cats¹¹
 - Makes **individualised accurate dosing** simple
 - **Is easily combined** with **renal diets, supplements and amlodipine**

*Reduction of proteinuria associated with chronic kidney disease in cats.

Semintra—a unique solution to protect the special cat-owner bond¹



Safety information



CATS:

- Dose for reduction of proteinuria is safe for use with amlodipine. Dose for reduction of blood pressure should not be used with other anti-hypertensive agents due to risk for hypotension and reduced renal function
- Transient hypotension and/or mild anaemia can occur due to down-modulation of the RAAS¹²
- It is good clinical practice to monitor¹²:
 - the blood pressure of cats under anaesthesia
 - the red blood cell count
- Safety has not been evaluated in pregnant or lactating cats, or kittens¹²

OWNERS AND CLINIC STAFF:

- Pregnant women should take special care to avoid contact with Semintra¹²

References



1. Taylor S, Sparkes AH. Feline CKD: new horizons - where do we go from here? *J Feline Med Surg.* 2013;15 Suppl 1:45–52.
2. Syme HM, Markwell PJ, Pfeiffer D, Elliott J. Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. *J Vet Intern Med.* 2006;20:528–535.
3. Sparkes AH, Caney S, Chalhoub S, et al. ISFM consensus guidelines on the diagnosis and management of feline chronic kidney disease. *J Feline Med Surg.* 2016;18:219–239.
4. Boyd LM, Langston C, Thompson K, Zivin K, Imanishi M. Survival in cats with naturally occurring chronic kidney disease (2000-2002). *J Vet Intern Med.* 2008;22:1111–1117.
5. Polzin DJ. Chronic kidney disease. In: Ettinger SJ, Feldman EC, Côté, E, eds. *Veterinary Internal Medicine.* 8th edition. St. Louis, MO: Elsevier; 2017:1938–1959.
6. IRIS Staging of CKD. International Renal Interest Society website. Available at: http://www.iris-kidney.com/pdf/IRIS_Staging_of_CKD_modified_2019.pdf. Accessed February 28, 2022.
7. Ray M, Carney HC, Boynton B, et al. 2021 AAEP feline senior care guidelines. *J Feline Med Surg.* 2021;23:613–638.
8. Quimby J, Gowland S, Carney HC, DePorter T, Plummer P, Westropp J. 2021 AAHA/AAFP feline life stage guidelines. *J Feline Med Surg.* 2021;23:211–233.
9. Sent U, Gössl R, Elliott J, Syme HM, Zimmering T. Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease. *J Vet Intern Med.* 2015;29:1479–1487. Erratum published in *J Vet Intern Med.* 2016;30:689.
10. Zimmering TM, Verena Heck E, Adams J. Effect of Semintra® and owner observations on quality of life effects in cats with chronic kidney disease – update on owner feedback (“EASY Programme”). Proceedings of the FECAVA EuroCongress; 15–17 October 2015; Barcelona, Spain.
11. Semintra Summary of Product Characteristics (SPC). European Medicines Agency website. Available at: https://www.ema.europa.eu/en/documents/product-information/semintra-epar-product-information_en.pdf. Accessed February 28, 2022.
12. Data on file. Boehringer Ingelheim Animal Health.